Methods and assays relating to huntingtons disease

Abstract

Described herein are methods for the diagnosis, prognosis, and treatment of neurological conditions, e.g. Huntington's Disease, relating to the misregulation of miRNAs in such conditions.

What is claimed herein is: 
     
         1 . A method comprising detecting the level of expression of at least one miRNA selected from the group consisting of:
 miR-10b-5p; miR196a-5p; miR196b-5p; miR615-3p; miR1247-5p; miR106a-5p; miR363-3p; and miR-129-1-3p in a sample obtained from a subject.   
     
     
         2 . The method of  claim 1 , wherein the subject has an htt3 mutation. 
     
     
         3 . The assay of  claim 1 , wherein the sample is selected from the group consisting of:
 a blood sample; blood plasma; cerebrospinal fluid; and a brain sample.   
     
     
         4 . The method of  claim 1 , wherein the level of at least three miRNAs is measured. 
     
     
         5 . The method of  claim 1 , wherein the level of at least four miRNAs is measured. 
     
     
         6 . The method of  claim 1 , wherein the level of at least five miRNAs is measured. 
     
     
         7 . The method of  claim 1 , wherein the level of at least six miRNAs is measured. 
     
     
         8 . The method of  claim 1 , wherein the level of at least seven miRNAs is measured. 
     
     
         9 . The method of  claim 1 , wherein the method further comprises detecting the level of expression of miR-132-3p in the sample. 
     
     
         10 . A method comprising detecting the level of expression of at least one miRNA selected from the group consisting of:
 miR-10b-5p; miR-151b; miR-29b-2-5p; miR-329-3p; miR-6511a-5p; miR-5690; miR-516b-5p; miR208b-3p; miR106a-5p; miR-363-3p; miR-4526; miR-129-1-3p; miR-129-2-3p; miR-132-3p; miR127-3p; miR212-3p; miR16-2-3p; miR-30a-3p; miR-132-5p; miR-212-5p; miR-145-5p; and miR-29a-5p in a sample obtained from a subject.   
     
     
         11 . The method of  claim 10 , wherein the subject is a Parkinson's Disease carrier. 
     
     
         12 . The method of  claim 10 , wherein the sample is selected from the group consisting of:
 a blood sample; blood plasma; cerebrospinal fluid; and a brain sample.   
     
     
         13 . The method of  claim 10 , wherein the level of at least three miRNAs is measured. 
     
     
         14 . The method of  claim 10 , wherein the level of at least four miRNAs is measured. 
     
     
         15 . The method of  claim 10 , wherein the level of at least five miRNAs is measured. 
     
     
         16 . The method of  claim 10 , wherein the level of at least six miRNAs is measured. 
     
     
         17 . The method of  claim 10 , wherein the level of at least seven miRNAs is measured. 
     
     
         18 . The method of  claim 10 , wherein the method further comprises detecting the level of expression of one or more miRNAs selected from the group consisting of:
 miR-132-5p; miR-212-3p; miR-1224-5p; miR-1294;   
       in the sample. 
     
     
         19 . An assay comprising
 (a) measuring, in a sample obtained from a subject, the level of at least one miRNA selected from the group consisting of:
 miR520f-3p, miR-135b-3p, miR-4317, miR-3928-5p, miR-8082, mir-140-5p; 
   (b) administering a potential treatment for Huntington's Disease;   (c) measuring, in a sample obtained from a subject, the level of the at least one miRNA selected from the group consisting of:
 miR520f-3p, miR-135b-3p, miR-4317, miR-3928-5p, miR-8082, mir-140-5p; 
   (d) determining that the potential treatment is efficacious in reducing the risk of Huntington's Disease developing or progressing if the level of the at least one miRNA measured in step (c) is not increased relative to the level measured in step (a) and determining that the potential treatment is not in reducing the risk of Huntington's Disease developing or progressing if the level of the miRNA measured in step (c) is increased relative to the level measured in step (a).